Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 04 Nov 2026
₹1,714.3
Change
-8.1 (-0.47%)
Open
₹1,650.0
Prev. Close
₹1,722.4
Day High
₹1,738.0
Day Low
₹1,600.1
Volume Analysis
Traded
77,675
Delivered
41,473
Delivery %
53.39%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,906.06 | ₹1,822.03 | ₹1,768.16 | ₹1,684.13 | ₹1,630.26 | ₹1,546.23 | ₹1,492.36 |
| Fibonacci | ₹1,822.03 | ₹1,769.35 | ₹1,736.81 | ₹1,684.13 | ₹1,631.45 | ₹1,598.91 | ₹1,546.23 |
| Camarilla | ₹1,752.22 | ₹1,739.58 | ₹1,726.94 | ₹1,684.13 | ₹1,701.66 | ₹1,689.02 | ₹1,676.38 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
—
1 Month
—
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 04 Nov 2026. Not investment advice.
TopFund Analysis
Evonile Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Corporate Governance (85/100), while Institutional Ownership (52/100) is the weakest area to weigh before deciding. FII holding has been rising.
TopFund Score — Fundamentals Quality
67/100 — GoodData confidence: 57/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 04 Nov 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Rights issue of up to ₹8,847.54 million at ₹860; record date November 11, 2026, ratio 5:12.
Intimation of the Newspaper publications made in Financial Express and Navshakti for the Financial Results pertaining to the quarter and half year ended September 30, …
Audio recording of November 4, 2026 earnings call for Q2 and half-year FY2026 uploaded online.
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 28.6% | 28.61% | 28.6% | 28.61% | 28.6% | 28.61% | 28.6% | 28.61% | 28.5% | 28.6% | 27.81% | 26.61% |
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.17% | 0.16% | 1.21% |
| DII | 0.52% | 0.52% | 0.52% | 0.52% | 0.53% | 0.53% | 0.53% | 0.53% | 0.63% | 0.53% | 1.35% | 1.5% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Evonile Pharma Limited (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 425,006 | 34.5 | 4.77 | 16.0% |
| Divi S Laboratories Ltd | 259,628 | 87.1 | 15.5 | 16.5% |
| Torrent Pharmaceuticals L | 176,090 | 81.1 | 9.55 | 27.4% |
| Laurus Labs Limited | 126,865 | 94.7 | 20.96 | 18.3% |
| Zydus Lifesciences Ltd | 124,239 | 25.5 | 4.63 | 21.2% |
| Apollo Hospitals Enter. L | 122,322 | 58.2 | 12.84 | 21.2% |
Which Mutual Funds Hold Evonile Pharma Limited?
Frequently Asked Questions about Evonile Pharma Limited
Evonile Pharma Limited (EVONILE) closed at ₹1,714.3 on NSE on 04 November 2026, down 8.1 (0.47%) from the previous close.
Evonile Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol EVONILE.
Evonile Pharma Limited has a TopFund Quality Score of 67/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Evonile Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.